Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.33 |
| ▸ | CDC25B | P30305 | 6/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667496 | 0.94 | PTPN1 (0.34) | PDE2APTPN1CDC25BHTR1ABCHE | |
| SCHEMBL18788247 | 0.94 | PDE2A (0.35) | PDE2APTPN1CDC25BHTR1ABCHE | |
| SCHEMBL19292338 | 0.91 | PDE2A (0.32) | PDE2APTPN1CDC25BHTR1ABCHE | |
| SCHEMBL20404007 | 0.87 | PDE2A (0.32) | PDE2AHSPA5 | |
| SCHEMBL17106669 | 0.86 | PTPN1 (0.34) | PDE2APTPN1CDC25BHTR1ABCHE | |
| SCHEMBL19412708 | 0.86 | PTPN1 (0.34) | PDE2APTPN1CDC25BHTR1ABCHE | |
| SCHEMBL23773046 | 0.85 | PDE4D (0.31) | PDE2A | |
| SCHEMBL23278055 | 0.85 | PDE2A (0.32) | PDE2AHSPA5 | |
| SCHEMBL12243144 | 0.85 | PDE2A (0.30) | PDE2A | |
| SCHEMBL12393237 | 0.85 | PDE2A (0.30) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132123-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |